Amgen’s Enbrel heads ICER list of unjustified US price risesUS cost effectiveness watchdog ICER found 10 examples of substantial price rises for top-selling medicines in 2019, and Share XAmgen’s Enbrel heads ICER list of unjustified US price riseshttps://pharmaphorum.com/news/icer-lists-top-unjustified-drug-price-rises-headed-by-amgens-enbrel/
Amgen hands off leprosy, TB candidate to Australian non-profitAmgen has decided that a drug for leprosy and tuberculosis it inherited as part of its acquisition of Share XAmgen hands off leprosy, TB candidate to Australian non-profithttps://pharmaphorum.com/news/amgen-hands-off-leprosy-tb-candidate-to-australian-non-profit/
AZ, Amgen’s asthma hope tezepelumab flunks phase 3 trialAstraZeneca and Amgen looked on course to cruise to approval of their severe asthma drug tezepelumab with a Share XAZ, Amgen’s asthma hope tezepelumab flunks phase 3 trialhttps://pharmaphorum.com/news/az-amgens-asthma-hope-tezepelumab-flunks-phase-3-trial/
Amgen files KRAS trailblazer sotorasib with FDA for lung cancerAmgen has filed its groundbreaking KRAS inhibiting drug sotorasib with the FDA for a group of lung cancer Share XAmgen files KRAS trailblazer sotorasib with FDA for lung cancerhttps://pharmaphorum.com/news/amgen-files-kras-inhibitor-with-fda/
Novartis’ Aimovig tops topiramate in migraine face-offNovartis’ injectable migraine prevention antibody Aimovig has been shown to be more effective than topiramate – a go-to Share XNovartis’ Aimovig tops topiramate in migraine face-offhttps://pharmaphorum.com/news/novartis-aimovig-tops-topiramate-in-migraine-face-off/
BMS’ deucravacitinib psoriasis pill outperforms Amgen’s Otezla in phase 3Bristol-Myers Squibb could be on the verge of a major coup in psoriasis after its deucravacitinib pill outperformed Share XBMS’ deucravacitinib psoriasis pill outperforms Amgen’s Otezla in phase 3https://pharmaphorum.com/news/bms-deucravacitinib-psoriasis-pill-outperforms-amgens-otezla-in-phase-3/
Scotland backs two myeloma drugs turned down by NICE in EnglandA north-south divide threatens to emerge in multiple myeloma in the UK, after the Scottish Medicines Consortium (SMC) Share XScotland backs two myeloma drugs turned down by NICE in Englandhttps://pharmaphorum.com/news/scotland-backs-two-myeloma-drugs-tuned-down-by-nice-in-england/
Amgen shares down as heart failure drug disappoints in phase 3 trialShares in Amgen were down nearly 7% after close of trading yesterday after the company’s heart failure drug Share XAmgen shares down as heart failure drug disappoints in phase 3 trialhttps://pharmaphorum.com/news/amgen-shares-down-7-after-heart-failure-drug-disappoints-in-phase-3-trial/
Amgen offers hope in KRAS-mutated cancer with sotorasib read-outLast year Amgen intrigued scientists and investors alike after announcing data showing it had produced the first drug Share XAmgen offers hope in KRAS-mutated cancer with sotorasib read-outhttps://pharmaphorum.com/news/amgen-offers-hope-in-kras/